SciELO - Scientific Electronic Library Online

 
vol.16 número3MRE in NAFLD: Promising but Further Validation is Required índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Annals of Hepatology

versión impresa ISSN 1665-2681

Resumen

CHINCHILLA-LOPEZ, Paulina; QI, Xingshun; YOSHIDA, Eric M.  y  MENDEZ-SANCHEZ, Nahum. The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma. Ann. Hepatol. [online]. 2017, vol.16, n.3, pp.328-330. ISSN 1665-2681.  http://dx.doi.org/10.5604/16652681.1235473.

The increase of incidences of Hepatocellular Carcinoma (HCC) will continue in the next decades. The therapies about hepatitis C infection has been questioned as a risk factor. Some authors emphasized that sustained virologic response (SVR) with interferon- based therapy reduced the risk of developing HCC. In contrast, some publications that to suggest an increasing risk of HCC in patients treated with Direct-Acting Antivirals (DAA). Whether these therapies are associated with an increased risk of HCC remains to be studied and continued long-term observational studies will be needed. The goal in HCV care needs to go beyond merely achieving an SVR.

Palabras llave : Liver; Cancer; Drugs; Hepatitis.

        · texto en Inglés     · Inglés ( pdf )